Traders should monitor for upcoming clinical trial data readouts in na-SPMS and other neurodegenerative indications. Positive human data could significantly increase stock value given the unmet medical need in Long COVID and neurodegenerative diseases.
Price Chart
Executive Summary
Tiziana Life Sciences announced positive preclinical data from a bioRxiv preprint showing that its intranasal foralumab reduces neuroinflammation and improves cognitive function in a mouse model of Long COVID. The data support the therapeutic potential of foralumab for treating Long COVID-related 'brain fog'.
Key Facts
- Positive preclinical data published on bioRxiv (not yet peer-reviewed) demonstrate intranasal foralumab reduces neuroinflammation, boosts brain Tregs, restores hippocampal neurogenesis, and improves short-term memory in a Long COVID mouse model.
- Study conducted by leading academic researchers including Dr. Akiko Iwasaki (Yale) and Dr. Howard L. Weiner (Harvard), who is also Chair of Tiziana's Scientific Advisory Board.
- Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development.
- Data support ongoing clinical programs in neurodegenerative diseases including non-active secondary progressive multiple sclerosis (na-SPMS), MSA, Alzheimer's, and ALS.
- Company previously showed favorable safety and clinical signals in na-SPMS patients with reductions in microglial activation via PET imaging.
Financial Impact
Non-dilutive, non-monetary scientific advancement with potential to increase valuation through de-risking of clinical development pathway.
Risk Factors
- Preclinical data not yet peer-reviewed and may not translate to human efficacy.
- Intranasal delivery is novel and faces regulatory and commercial adoption hurdles.
- Company remains pre-revenue with high dependence on clinical trial outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-044318 |
| Document: ea0286617-6k_tiziana.htm | 0001213900-26-044318 |
| Document: 0001213900-26-044318-index-headers.html | 0001213900-26-044318 |
| Document: 0001213900-26-044318-index.html | 0001213900-26-044318 |
| Document: 0001213900-26-044318.txt | 0001213900-26-044318 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (−11.81%) |
Oct 16, 2026 9d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (+11.81%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8907 (−15.17%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8907 (−19.76%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 | awaiting T+20 | — | $0.8907 (−9.11%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8907 (−1.54%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8907 (−22.55%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8907 (−8.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers